CHCWM – Cancer & Hematology Centers of West Michigan

KL264-01 (Klus)

Description:   A Phase I-II, First –in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies

Mechanism of Action: Antibody drug conjugate to TROP-2.  This drug is very similar to Sacituzumab which has FDA approval in TNBC. 

Target Patient Population: .  Currently only open for gastric cancer. 

Study Design:   Drug is given IV every 2 weeks